Not medical advice. A record of published research and our assessments of it. The limits

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
NCT07241390 on ClinicalTrials.gov

Status: RecruitingResults none
Why it is watched: non-weight indication: cardiovascular, kidney
Who it enrolls: age 50 Years to no upper limit; excludes diabetes; no BMI minimum stated; conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Interventions: Orforglipron; Placebo
Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Phase and size: Phase 3 · 7140 participants
Dates: Start 2025-12-01
Primary completion 2031-08
Sponsor: Eli Lilly and Company (Industry)
Last checked: Sep 13, 2026

01Endpoints

What the trial will measure

Time to First Occurrence of Composite Endpoint of Major Cardiovascular EventsBaseline up to end of study (about 5 years)

02Eligibility

Who can take part

Inclusion Criteria: * Have established ASCVD and/or CKD Exclusion Criteria: * Have type 1 diabetes * Have had a major heart condition within 60 days prior to screening * Have New York Heart Association Functional Classification Class IV heart failure

03Change log

Registry changes

No changes recorded since the trial was added.